专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100189750A1 METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES 有权
标题翻译：在免疫特异性位点治疗肿瘤的方法
公开(公告)号：US20100189750A1
公开(公告)日：2010-07-29
申请号：US12677543
申请日：2008-09-11
申请人： Ilan Volovitz , Lea Eisenbach , Irun R. Cohen , Zvi Ram , Shimon Slavin
发明人： Ilan Volovitz , Lea Eisenbach , Irun R. Cohen , Zvi Ram , Shimon Slavin
IPC分类号： A61K39/00 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/5152
摘要： A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.
摘要翻译：提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答从而治疗受试者的免疫特异部位的癌症。

2. 发明授权

US08741315B2 Methods of treating tumors in immune-privileged sites 有权
标题翻译：治疗免疫特异部位肿瘤的方法
公开(公告)号：US08741315B2
公开(公告)日：2014-06-03
申请号：US12677543
申请日：2008-09-11
申请人： Ilan Volovitz , Lea Eisenbach , Irun R. Cohen , Zvi Ram , Shimon Slavin
发明人： Ilan Volovitz , Lea Eisenbach , Irun R. Cohen , Zvi Ram , Shimon Slavin
IPC分类号： A61K39/00 , A61K35/30
CPC分类号： A61K39/0011 , A61K2039/5152
摘要： A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.
摘要翻译：提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答从而治疗受试者的免疫特异部位的癌症。

3. 发明授权

US10421961B2 Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells 有权
公开(公告)号：US10421961B2
公开(公告)日：2019-09-24
申请号：US13377558
申请日：2010-06-10
申请人： Chaya Brodie , Shimon Slavin
发明人： Chaya Brodie , Shimon Slavin
IPC分类号： C12N15/113 , C12N5/0793 , A61K31/7105
摘要： Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.

4. 发明申请

US20130149288A1 METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME 有权
标题翻译：产生含有寡糖的小鼠和细胞群体的方法
公开(公告)号：US20130149288A1
公开(公告)日：2013-06-13
申请号：US13817535
申请日：2011-08-14
申请人： Shimon Slavin , Chaya Brodie
发明人： Shimon Slavin , Chaya Brodie
IPC分类号： C12N5/079
CPC分类号： C12N5/0622 , A61K35/12 , C12N15/113 , C12N2310/141 , C12N2320/30 , C12N2330/10 , C12N2500/25 , C12N2501/39 , C12N2501/65 , C12N2506/025 , C12N2506/1353 , C12N2506/1384 , C12N2506/1392
摘要： A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.
摘要翻译：公开了一种产生可用于治疗受试者脑部疾病的细胞群的方法。所述方法包括使间充质干细胞（MSC）与至少一种外源miRNA接触，所述外源miRNA具有与选自SEQ ID NO：15-19和27-35的序列至少90％相同的核酸序列，从而产生细胞群和/或产生神经营养因子，其可以向受损组织或局部驻留的干细胞提供重要信号。通过miR分化的MSC也可以分泌miR并将其递送至相邻细胞，并因此向相邻内源性正常或恶性细胞提供重要信号。

5. 发明申请

US20100311841A1 SYNTHETIC SPHINGOLIPID ANALOGS 审中-公开
标题翻译：合成弹性体类似物
公开(公告)号：US20100311841A1
公开(公告)日：2010-12-09
申请号：US12742036
申请日：2008-11-06
申请人： Arie Dagan , Shimon Gatt , Shimon Slavin
发明人： Arie Dagan , Shimon Gatt , Shimon Slavin
IPC分类号： A61K31/135 , C07C213/00
CPC分类号： C07C323/32 , C07C381/12
摘要： Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.
摘要翻译：提供了基于合成鞘脂类似物的治疗化合物，特别是烷基硫代苯基取代的神经酰胺类似物，其适于治疗退行性，感染性和其它疾病。

6. 发明授权

US07347999B2 Methods of treatment of hematopoietic disorders 有权
标题翻译：造血障碍治疗方法
公开(公告)号：US07347999B2
公开(公告)日：2008-03-25
申请号：US10471048
申请日：2002-03-05
申请人： Shimon Slavin , Olga Gurevitch , Basan Gowda S. Kurkalli , Tatyana Prigozhina
发明人： Shimon Slavin , Olga Gurevitch , Basan Gowda S. Kurkalli , Tatyana Prigozhina
IPC分类号： A61K35/32 , A61K35/28
CPC分类号： A61K35/32 , A61K35/28 , A61K38/1875 , A61K2300/00
摘要： A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.
摘要翻译：包含骨髓细胞（BMC）和去矿物质骨基质（DBM）和/或矿化骨基质（MBM）的组合物，任选地包括骨形态发生蛋白（BMP），特别是用于骨髓移植，进入骨髓腔或骨骼外位点及其移植/植入方法。本发明的组合物和方法能够恢复和/或增强源自移植的BMC的造血微环境的形成，并且可用于治疗造血障碍，例如干细胞和/或其产物的缺乏，导致异常干细胞和/或产物，或恶性或非恶性起源的造血障碍。本发明的组合物和方法也可用于诱导移植物穿刺，用于预防移植物抗宿主病。最重要的是，本发明的组合物和方法可以用于治疗主要或二次影响支持和调节造血的基质微环境的疾病。还提供了用于与DBM和/或MBM混合的用于移植到BMC的哺乳动物中的试剂盒。

7. 发明申请

US20070099987A1 Treating or preventing diabetes with cannabidiol 有权
标题翻译：用大麻素治疗或预防糖尿病
公开(公告)号：US20070099987A1
公开(公告)日：2007-05-03
申请号：US10589623
申请日：2005-02-16
申请人： Lola Weiss , Michael Zeira , Raphael Mechoulam , Shimon Slavin , Ruth Gallily
发明人： Lola Weiss , Michael Zeira , Raphael Mechoulam , Shimon Slavin , Ruth Gallily
IPC分类号： A61K31/353 , A61K31/192 , A61K31/05
CPC分类号： A61K31/05 , A61K36/185
摘要： Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
摘要翻译：使用大麻二醇来制造用于治疗或预防糖尿病和/或胰岛炎的药物。

8. 发明授权

US06428782B1 Non-myeloablative tolerogenic treatment 有权
标题翻译：非清髓性耐受性治疗
公开(公告)号：US06428782B1
公开(公告)日：2002-08-06
申请号：US09222011
申请日：1998-12-31
申请人： Shimon Slavin , Tatyana Prigozhina
发明人： Shimon Slavin , Tatyana Prigozhina
IPC分类号： A61K3800
CPC分类号： A01K67/0271 , A61K35/17 , A61K35/28 , A61K39/001 , A61K2039/5158
摘要： The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.
摘要翻译：本发明的特征在于在宿主中诱导供体特异性耐受的方法。本发明的耐受性治疗可以在移植供体来源的材料之前施用于宿主。耐受性治疗涉及（1）以足以减少但不一定消除宿主哺乳动物功能性T淋巴细胞群体的非骨髓清除方案向宿主哺乳动物施用免疫抑制剂; （2）将来自非同基因供体的供体抗原输入宿主哺乳动物; （3）使用非清髓剂量的淋巴细胞毒性或耐受剂消除对输注的供体抗原的响应的宿主T淋巴细胞; 和（4）向宿主哺乳动物施用供体造血细胞。用于宿主哺乳动物细胞治疗的供体淋巴细胞可以通过基本上类似于用于在移植前耐受宿主哺乳动物的那些方法来消耗宿主特异性免疫反应性。

9. 发明公开

US20230241240A1 MULTIFUNCTIONAL IMMUNOTHERAPEUTIC MONOCLONAL ANTIBODY COMPLEXES AND CONJUGATES 审中-公开
公开(公告)号：US20230241240A1
公开(公告)日：2023-08-03
申请号：US18001542
申请日：2021-06-14
申请人： Shimon Slavin
发明人： Shimon Slavin
IPC分类号： A61K47/68 , A61P35/00 , A61K39/395 , A61K35/17 , C07K16/28 , A61K38/20
CPC分类号： A61K47/6849 , A61P35/00 , A61K39/3955 , A61K35/17 , C07K16/2887 , C07K16/2809 , C07K16/2818 , A61K38/2013 , C07K2317/54 , C07K2317/52 , A61K2039/5158
摘要： Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

10. 发明授权

US08609736B2 Telomerase activating compounds and methods of use thereof 有权
标题翻译：端粒酶活化化合物及其使用方法
公开(公告)号：US08609736B2
公开(公告)日：2013-12-17
申请号：US12602956
申请日：2008-06-04
申请人： Aviv Gazit , Shimon Slavin , Esther Priel , Sara Yitzchak
发明人： Aviv Gazit , Shimon Slavin , Esther Priel , Sara Yitzchak
IPC分类号： A01N31/14 , A01N33/02 , A61K31/075 , A61K31/135 , C09B11/02 , C07D211/08
CPC分类号： C07C215/80 , A61K31/03 , A61K31/05 , A61K31/055 , A61K31/136 , A61K31/66 , A61K31/695 , C07C39/367 , C07C43/225 , C07C43/23 , C07C215/50 , C07D213/16 , C07D213/30 , C07D295/096 , C07D295/135 , C07F9/5022
摘要： The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.
摘要翻译：本发明涉及一系列化合物和包含其的组合物用于活化端粒酶和治疗与之相关的疾病，病症和/或病症的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式